Exercise of Warrants
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for treating cancer, announces that it has today issued 5,000,000 new ordinary shares at a subscription price of 1 penny each pursuant to the exercise of warrants.
Issue of Further Shares and Warrants
In accordance with the Supplemental Agreement with Brahma AG announced on 2 April 2015, the Company announces that it has today issued 3,737,169 new ordinary shares and 4,216,293 five year warrants. The Warrants are exercisable at a price of 8.25p per share. The issue of the Further Shares and Warrants fully completes the Company’s obligations under the Agreement.
Application has been made for the 5,000,000 Warrant Shares and the 3,737,169 Further Shares to be admitted to trading on AIM and it is expected that Admission will occur on 22 May 2015. The Shares will rank pari passu in all respect with the existing Shares of the Company.
Total voting rights
Following Admission, the Company’s enlarged issued share capital will comprise 1,347,922,626 Shares, with voting rights. The Company does not hold any Shares in treasury. Therefore the total number of Shares in the Company with voting rights will be 1,347,922,626. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.
For further information, please contact:
Advanced Oncotherapy Plc
Sanjeev Pandya, CEO
Tel: +44 20 3617 8728
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten
Tel: +44 20 7601 6100
Beaufort Securities (Joint Broker)
Saif Janjua / Jon Levinson
Tel: +44 20 7382 8300
Walbrook PR (Financial PR & IR)
Tel: +44 20 7933 8780 or email@example.com
Paul McManus / Anna Dunphy
Mob: +44 7980 541 893 / Mob: +44 7876 741 001